These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37919070)

  • 1. Overexpression of PSAT1 is Correlated with Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer.
    Li H; Wu C; Chang W; Zhong L; Gao W; Zeng M; Wen Z; Mai S; Chen Y
    Front Biosci (Landmark Ed); 2023 Oct; 28(10):243. PubMed ID: 37919070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 5. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
    Liu X; Ma C; Liu H; Sun Z; Luo J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
    Li C; Pan J; Luo J; Chen X
    BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSAT1 regulates cyclin D1 degradation and sustains proliferation of non-small cell lung cancer cells.
    Yang Y; Wu J; Cai J; He Z; Yuan J; Zhu X; Li Y; Li M; Guan H
    Int J Cancer; 2015 Feb; 136(4):E39-50. PubMed ID: 25142862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.
    Luo L; Li A; Fu S; Du W; He LN; Zhang X; Wang Y; Zhou Y; Yunpeng Y; Li Z; Hong S
    Immunol Res; 2023 Apr; 71(2):213-228. PubMed ID: 36434349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 10. KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer.
    Zhou X; Wang N; Zhang Y; Yu H; Wu Q
    Invest New Drugs; 2022 Feb; 40(1):43-57. PubMed ID: 34499335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy.
    Feng M; Cui H; Tu W; Li L; Gao Y; Chen L; Li D; Chen X; Xu F; Zhou C; Cao Y
    Front Genet; 2022; 13():975381. PubMed ID: 36105075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer.
    Chen D; Zhang H; Zhao L; Liu X; Xue S; Wu P; Jiang H
    Cell Cycle; 2023 Apr; 22(7):841-857. PubMed ID: 36536539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
    Wang M; Yue S; Yang Z
    Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. circRNA-mediated upregulation of HOXC9 is correlated with poor outcome and immune microenvironment infiltrates in LUAD.
    Liu Y; Jing L; Zhang J
    Biochem Biophys Res Commun; 2022 Dec; 635():128-135. PubMed ID: 36272177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy.
    Luo L; Fu S; Du W; He LN; Zhang X; Wang Y; Zhou Y; Hong S
    Front Immunol; 2023; 14():959868. PubMed ID: 36798137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.